A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Transit Scientific Announces the Close of Its Series A financing Round

February 3, 2021

Transit Scientific today announced the close of its Series A financing round. The round was led by a large multinational investor and joined by previous seed investors.

Transit Scientific achieved FDA clearances and multi-center, multi-user, safe-patient-use of its XO Score angioplasty scoring-cutting platform and separate XO Cross 0.014″ and 0.035″ microcatheter platform in late 2020.

“XO Score successfully dilated multiple lesions that were resistant to standard or high-pressure balloon angioplasty during our 1st patient uses in hemodialysis fistulas,” said Jeffrey Hoggard MD, of the Raleigh Access Center in Raleigh, North Carolina, USA. “It was particularly beneficial to be able to deploy the XO Score device with a standard PTA balloon in the juxta-anastomotic position and dilate the lesion at low and controlled inflation pressure.”

The XO Score is a novel sheath that converts regular angioplasty balloons into vessel prep scoring and cutting systems. The device is indicated for treatment of peripheral vascular stenosis including hemodialysis fistulas and grafts.

XO Score’s 22 individual scoring & cutting struts rotate 90 degrees to score & cut upon balloon inflation and then rotate 90 degrees back upon balloon deflation to facilitate balloon re-wrap. The technology also allows for infusion at the site of treatment.

“The XO Cross 014, 018, and 035 microcatheter platform adds new torque, pushability and catheter control,” said Richard Saxon, MD, FSIR of the Tri-City Medical Center in Oceanside, CA, USA  “We have used an .014 XO Cross to redirect the guidewire intraluminally while crossing a tibial artery CTO. This would have been very difficult to achieve with other available technology.”

The XO Cross is a non-tapered exoskeleton based micro-catheter technology designed to improve torque response, trackability, and control.

“We are grateful to have smart value-added investors,” said Greg Method, president and chief executive officer of Transit Scientific. “Our team puts patients first and achieved a great deal in 2020 including FDA clearances and, most importantly, safe-patient-uses in a variety of challenging procedures with cardiologists, interventional radiologists, nephrologists, and vascular surgeons at different locations.”

Transit Scientific is a private company that designs, develops, and commercializes medical devices including the FDA-cleared XO ScoreÒ scoring sheath and  XO CrossÒ microcatheters.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Research teams led by a faculty member in Purdue University’s College of Engineering will use two grants from the National Eye Institute totaling $6.7 million to further develop specialized smart soft contact lenses that continuously monitor or treat chronic ocular diseases like glaucoma, corneal neovascularization and dry eye syndromes.
The series B funding round saw participation from venture capital firms Blume Ventures, Steadview Capital, Nexus Venture Partners, Alpha Wave and Zomato founder Deepinder Goyal. Ultrahuman will deploy the funds towards building further manufacturing capacity and deeper research in the health tracking space notes Ultrahuman.
Bone Health Technologies Bone Health Technologies (BHT), a health technology innovator developing breakthrough non-invasive solutions for bone health, today announced the company has raised a...
Howard Robin, President and Chief Executive Officer of Nektar Therapeutics: "We are pleased to bring on TCGX as a new high-quality, long-term investor in Nektar as we advance rezpegaldesleukin through our Phase 2b studies in atopic dermatitis and alopecia areata. We are on track to report topline data from these studies in the first half of 2025, which will represent significant inflection points for Nektar. Today's financing further bolsters our financial position and extends the company's cash runway well into the third quarter of 2026."
MMI notes the funds will support commercialization of the Symani® Surgical System in high-growth markets and continued investment in studies that generate clinical evidence and enable indication expansion. Investments will also accelerate advanced technology capabilities and enable MMI to scale its operational capabilities globally.

By using this website you agree to accept Medical Device News Magazine Privacy Policy